Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

First-line use of EGFR tyrosine kinase inhibitors in patients with NSCLC containing EGFR mutations.

Clinical advances in hematology & oncology : H&O - 1 Feb 2010

Neal Joel W, Sequist Lecia V

Abstract excerpt

While the small molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors erlotinib and gefitinib have modest clinical benefit in unselected patients with non-small cell lung cancer after platinum-based chemotherapy, an emerging and potentially more elegant strategy is to move these agents to the frontline setting for select patients. Those with somatic mutations in EGFR respond dramatically to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Clinical Trials as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Erlotinib Hydrochloride

Share to Gefitinib

Share to Patient Selection

Share to Protein Kinase Inhibitors

Share to Quinazolines

Share to Survival Analysis

Source

Identifiers

PMID: 20386533

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

First-line use of EGFR tyrosine kinase inhibitors in patients with NSCLC containing EGFR mutations.PMID 20386533Read ↗

Pharmacotherapy targeting the EGFR oncogene in NSCLC.Semantic proximity Read ↗

Update of epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer.Semantic proximity Read ↗

EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer.Semantic proximity Read ↗

Which tyrosine kinase inhibitor should be recommended as initial treatment for non-small cell lung cancer patients with EGFR mutations?Semantic proximity Read ↗

EGFR inhibitors as the first-line systemic treatment for advanced non-small-cell lung cancer.Semantic proximity Read ↗

EGFR tyrosine kinase inhibitors in lung cancer: an evolving story.Semantic proximity Read ↗

A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives.Semantic proximity Read ↗

Erlotinib in the first-line treatment of non-small-cell lung cancer.Semantic proximity Read ↗

Erlotinib : a guide to its use in first-line treatment of non-small-cell lung cancer with epidermal growth factor-activating mutations.Semantic proximity Read ↗

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.Semantic proximity Read ↗

Targeting epidermal growth factor receptor: central signaling kinase in lung cancer.Semantic proximity Read ↗

Targeting epidermal growth factor receptor in the treatment of non-small-cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.